Incidence and characteristics of angioedema associated with enalapril

Archives of Internal Medicine

Volumn 165, Issue 14, 2005, Pages 1637-1642

  Kostis, John B ^a   Kim, Harold J ^a   Rusnak, James ^b   Casale, Thomas ^c   Kaplan, Allen ^d   Corren, Jonathan ^e   Levy, Elliott ^b  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e Allergy Research Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANTIHISTAMINIC AGENT; CORTICOSTEROID; ENALAPRIL MALEATE; OMAPATRILAT;

ADULT; AGED; ALLERGY; ANGIONEUROTIC EDEMA; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYPERTENSION; INCIDENCE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; RISK ASSESSMENT; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ANGIONEUROTIC EDEMA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; DOUBLE-BLIND METHOD; ENALAPRIL; FEMALE; HUMANS; HYPERTENSION; INCIDENCE; LOGISTIC MODELS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 23744447222     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.165.14.1637     Document Type: Article

References (22)

1. Ondetti MA, Rubin B, Cushman DW. Design of specific inhibitors of angiotensin-converting enzyme: a new class of orally active antihypertensive agents. Science. 1977;196:441-444.
2. Kostis JB. Angiotensin converting enzyme inhibitors, II: clinical use. Am Heart J. 1988;116:1591-1605.
3. Klein L, O'Connor CM, Gattis WA, et al. Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations. Am J Cardiol. 2003;91:18F-40F.
4. Poole-Wilson PA. ACE inhibitors and ARBs in chronic heart failure: the established, the expected, and the pragmatic. Med Clin North Am. 2003;87:373-389.
5. Flather MD, Yusuf S, Kober L, et al; ACE-Inhibitor Myocardial Infarction Group.Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet. 2000;355:1575-1581.
6. Genest J, Pedersen TR. Prevention of cardiovascular ischemic events: high-risk and secondary prevention. Circulation. 2003;107:2059-2065.
7. Rodrigues EJ, Eisenberg MJ, Pilote L. Effects of early and late administration of angiotensin-converting enzyme inhibitors on mortality after myocardial infarction. Am J Med. 2003;115:473-479.
8. Lewis EJ. The role of angiotensin II receptor blockers in preventing the progression of renal disease in patients with type 2 diabetes. Am J Hypertens. 2002;15:123S-128S.
9. Brewster UC, Perazella MA. The rennin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am J Med. 2004;116:263-272.
10. Thompson JS. Urticaria and angioedema. Ann Intern Med. 1968;69:361-380.
11. Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs Enalapril (OCTAVE) Trial. Am J Hypertens. 2004;17:103-111.
12. Wilkin JK, Hammond JJ, Kirkendall WM. The captopril-induced eruption: a possible mechanism: cutaneous kinin potentiation. Arch Dermatol. 1980;116:902-905.
13. Vleeming W, van Amsterdam JG, Stricker BH, de Wildt DJ. ACE inhibitor-induced angioedema: incidence, prevention and management. Drug Saf. 1998;18:171-188.
14. Slater EE, Merrill DD, Guess HA, et al. Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition. JAMA. 1988;260:967-970.
15. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy: a review of the literature and pathophysiology. Ann Intern Med. 1992;117:234-242.
16. Kostis JB, Wilson AC. Incidence of angioedema in SOLVD [abstract]. J Am Coll Cardiol. 2002;39(suppl A):166A.
17. Kostis JB, Shelton B, Gosselin G, et al; SOLVD Investigators. Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). AmHeart J. 1996;131:350-355.
18. Burkhart DG, Brown NJ, Griffin MR, Ray WA, Hammerstrom T, Weiss S. Angiotensin converting enzyme inhibitor-associated angioedema: higher risk in blacks than whites. Pharmacoepidemiol Drug Saf. 1996;5:149-154.
19. Brown NJ, Ray WA, Snowden M, Griffin MR. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther. 1996;60:8-13.
20. Agostoni A, Cicardi M, Cugno M, Zingale LC, Gioffre D, Nussberger J. Angioedema due to angiotensin-converting enzyme inhibitors. Immunopharmacology. 1999;44:21-25.
21. Dean DE, Schultz DL, Powers RH. Asphyxia due to angiotensin converting enzyme (ACE) inhibitor mediated angioedema of the tongue during the treatment of hypertensive heart disease. J Forensic Sci. 2001;46:1239-1243.
22. Hedner T, Sameulsson O, Lunde H, Lindholm L, Andren L, Wiholm BE. Angiooedema in relation to treatment with angiotensin converting enzyme inhibitors. BMJ. 1992;304:941-946.